What does this mean? The decision calls on the EU Commission to "secure rapidly and efficiently its supply of affordable medicines, medical equipment, medical devices, active substances, diagnostic tools and vaccines, and to prevent shortages thereof". Among the options identified are the following:
Encouraging the return of pharmaceutical manufacturing to Europe, including through financial incentives.
Safeguarding existing pharmaceutical production in Europe, e.g. by encouraging investment in the quality and safety of the pharmaceutical supply.
Taking account of investments in the production of active substances and finished products in the EU in tendering procedures.
Taking into account the number of production sites and investment in research and development in tendering procedures.
Sourcing from several manufacturers, preferably with production facilities in the EU.
Drafting of a directive setting minimum standards for health systems in the Member States.